Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response

Clin Cancer Res. 2020 May 15;26(10):2434. doi: 10.1158/1078-0432.CCR-20-0790.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Antineoplastic Agents, Immunological* / adverse effects
  • Humans
  • Ipilimumab / therapeutic use
  • Melanoma* / drug therapy
  • Melanoma* / genetics
  • Nivolumab / therapeutic use

Substances

  • Antineoplastic Agents, Immunological
  • Ipilimumab
  • Nivolumab